Compare Blackstone Inc (BX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Recursion Pharmaceuticals Inc — how do they compare? Blackstone Inc trades at $147.17 (market cap $113.32B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Blackstone Inc is far larger — about 63.7× Recursion Pharmaceuticals Inc's market cap, and Blackstone Inc pays a 3.69% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BX | RXRX | |
|---|---|---|
Market Cap | $113.32B | $1.78B |
Sector | Financials | Health |
52-Week High | $188.68 | $6.79 |
52-Week Low | $102.12 | $2.84 |
Dividend Yield | 3.69% | — |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone Inc. (BX) trades at $137.13, up 2.76% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41 billion in 2025, with a net income margin of 25.85%, while analyst consensus is a Buy with a $144.00 price target. Recent news includes a $16 billion Kuwait oil pipeline deal and the acquisition of a $25.3 billion Australian loan portfolio from HSBC, highlighting strategic expansion.
The outlook for BX is positive, driven by robust earnings growth and strategic acquisitions, but risks include market volatility and sector-specific pressures. Upside potential exists toward the consensus target, though overbought RSI levels near-term may prompt consolidation.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
